Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
# |3 }' z& M( c7 U0 I5 ?
9 y' m4 n* e5 a4 E' Q e' ^7 u q4 l- w) Z! y* R- {
Sub-category:8 E0 q5 q- }" r1 u0 w* V
Molecular Targets 2 m" s8 c( ^* p/ l/ w' i6 `
% n: R A+ U, `! {: n& ~* P ?/ A$ d3 z% j' W% D/ J
Category:
* o4 ]& k' s( b# Q5 O Z1 q6 m( OTumor Biology / a9 A# `; J3 l$ d3 n# z) _
$ A1 I6 k% M) }% a, _
& x! w- p8 X. C& D" R2 } I* FMeeting:7 H Q7 b7 n) @, @
2011 ASCO Annual Meeting
+ R" ^9 @% J6 O( G! a9 v: Z9 m% s) ^3 W+ }* R) |4 q
5 e/ A. W; N8 V* `: Y. iSession Type and Session Title:& D. u- W, f" i0 o5 Z
Poster Discussion Session, Tumor Biology - O/ \2 \1 E U
! v, F0 M$ V/ B. n6 \9 Z: \1 W2 B$ E) w3 U
Abstract No:- n! Q" P8 _- [% b/ P
10517
6 B5 F4 E9 C+ T0 j8 R2 t+ P) _$ o7 ?0 \5 k2 K' P' F
9 Q( G* z ?% t4 aCitation:
1 l* h' E" g9 D% vJ Clin Oncol 29: 2011 (suppl; abstr 10517)
3 z0 `! F$ I2 q1 l! n
. b( R6 u% |5 M* M0 z6 k, U' P
+ M; ]! B! a3 E6 w- [. ?; WAuthor(s):
# S( H9 ^) o: {" d3 nJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 4 H" P; }% l& s
- ]8 M" K% Y$ Y+ w% E
! `- I% C. A( ~+ {' Z- l/ m
5 n% L/ }3 b& `$ _Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.7 F+ c" N; F- H1 T% o! d4 D7 u8 d
! g0 S& X7 b7 ^# H6 EAbstract Disclosures
; V J; p: r$ R5 a' ?6 H- ]" \8 Z4 k! r
Abstract:
" g3 m) y4 j5 r- X% r" m. M8 c+ R: N( r0 S" j
j/ V& V) ?. }/ Q$ WBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.& G5 y% z1 b. W. E7 X
' w. p: O9 g, ?, o- t. d
- u1 b. k7 p1 [" |/ z- E& ?0 D |
感慨！！！一个非常令人伤感的病例
今天有时间，可以完整的听“中国胸部肿瘤大会诊——襄阳站”的MDT直播，第一个病例让
大家见过这种病理吗
两肺都有，不知道是两个原发还是转移？各位老师，帮忙分析一下原因，看看下步该怎么走
抗癌3年从晚期癌症到成功实现癌症治
讲述者：柳廷整理者：pear2022年2月，我确诊了最凶险的晚期三阴性乳腺癌，发现时已有
23年脑膜转，目前脑部稳定，肺原发灶
2025.3至2025.5.22脑实质和脑膜稳定，肺部原发灶及胸腔积液控制不住。CEA持续升高。
长期服用阿来耐药后，洛拉、放疗快速
一、患者主要治疗经过
患者2015年肺癌手术后，2019年底脑多发转移（原发无病灶），20
显身卡
